Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, novembre 04
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Merck & Co Inc
MRK
NYSE
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$144.67
-3.69
-2.49%
Ult. Agg.: Nov 3, 7:40 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Dividendi
Confronta
Opzioni
Rapporto azionario
Utili:
I risultati di Q3 2026 sono stati pubblicati in data gio ott 29th, prima dell'apertura del mercato
Conference call:
La conference call più recente è iniziata alle 9:00 AM, 6 giorni fa
Clicca per vedere il webcast
Merck & Co Financials
Merck & Co (MRK) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Merck's Keytruda Franchise Expands, Signals 'Modest' Revenue Growth in 2027
Merck beats Q3 estimates and raises 2026 guidance as Keytruda and Winrevair propel quarterly sales past Wall Street expectations.
Vandana Singh
Alphabet Sinks 11.8%, Small Caps Rally on Strong GDP Growth: Stock Market Today
Alphabet's capex-heavy quarter drags the Nasdaq 100 lower while GDP beats and the Russell 2000 rallies, with three of four large caps rising.
Piero Cingari
PRO
Merck & Co Raises FY2026 Adj EPS Guidance from $2.66-$2.76 to $2.77-$2.82 vs $2.65 Est; Raises FY2026 Sales Guidance from $66.300B-$67.300B to $66.800B-$67.300B vs $67.052B Est
Merck & Co (NYSE:MRK) raises FY2026 Adj EPS guidance from $2.66-$2.76 to $2.77-$2.82 vs $2.65 analyst estimate. Raises FY2026 sales outlook from $66.300 billion-$67.300 billion to $66.800 billion-$67.300 billion vs
Benzinga Newsdesk
PRO
Merck Q3 KEYTRUDA/KEYTRUDA QLEX Sales $8.60B (+6% Y/Y)
Total Worldwide Sales Were $18.1 Billion (5% Growth; 4% Growth ex-FX)KEYTRUDA/KEYTRUDA QLEX1 Sales Were $8.6 Billion (6% Growth; 6% Growth ex-FX); Includes KEYTRUDA QLEX Sales of $830 MillionWINREVAIR Sales Were $694
Benzinga Newsdesk
PRO
Merck & Co Q3 Adj. EPS $2.49 Beats $2.08 Estimate, Sales $18.085B Beat $17.313B Estimate
Merck & Co (NYSE:MRK) reported quarterly earnings of $2.49 per share which beat the analyst consensus estimate of $2.08 by 19.71 percent. This is a 3.49 percent decrease over earnings of $2.58 per share from the
Benzinga Newsdesk
Stock Market: Will S&P 500 Open Up or Down Today?
Will S&P 500 open higher? Polymarket odds dip to 47% as Wall Street weighs a tech selloff, Amazon earnings, PCE inflation, and cooling oil.
Rishabh Mishra
